Cerus Stock Forecast, Price & News

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS stock has increased by 22.9% and is now trading at $5.85.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus.

Wall Street analysts have given Cerus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cerus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cerus is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Cerus.

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings results on Thursday, October, 29th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04. Cerus had a negative net margin of 73.72% and a negative return on equity of 63.47%.
View Cerus' earnings history.

Cerus updated its FY 2020 After-Hours earnings guidance on Thursday, October, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-91 million, compared to the consensus revenue estimate of $112.46 million.

4 brokers have issued 1 year target prices for Cerus' stock. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' share price to reach $7.63 in the next twelve months. This suggests a possible upside of 30.3% from the stock's current price.
View analysts' price targets for Cerus.

Some companies that are related to Cerus include Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), OraSure Technologies (OSUR), Meridian Bioscience (VIVO), Anika Therapeutics (ANIK) and Antares Pharma (ATRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (18.05%), BlackRock Inc. (8.13%), Nikko Asset Management Americas Inc. (5.84%), State Street Corp (2.72%), Paradigm Capital Management Inc. NY (1.02%) and Peregrine Capital Management LLC (0.95%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Squarepoint Ops LLC, Cubist Systematic Strategies LLC, BlackRock Inc., Victory Capital Management Inc., Lesa Sroufe & Co, Charles Schwab Investment Management Inc., and Wells Fargo & Company MN. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

CERS stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, First Midwest Bank Trust Division, Morgan Stanley, Paradigm Capital Management Inc. NY, State Street Corp, Peregrine Capital Management LLC, Sei Investments Co., and Jackson Creek Investment Advisors LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $5.85.

Cerus has a market capitalization of $977.78 million and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 254 workers across the globe.

The official website for Cerus is www.cerus.com.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]